Sam Shrivastava

Company: ASHA therapeutics

Job title: Chief Executive Officer

Seminars:

Beyond KRAS: A Novel Constitutively-Active Pan-RAS Degrader 1:00 pm

Selectively targets constitutively active forms of RAS mutants Robust against mutation and overexpression resistance mechanisms Able to target all RAS isoformsRead more

day: Day Two Track A

Panel Discussion: Now We Have Successfully Targeted RAS G12C, What’s Next? 5:00 pm

As we close out two days dedicated to critical updates and project successes from across this community, this panel will dive into a discussion considering what is next for therapeutics targeting RAS-mutant cancers. After 40 years of dedicated science and significant progress, it is critical we expand the landscape of RAS targeted therapies beyond G12C…Read more

day: Day Two